Performance
Stock factor profile
GUFIC BIO SC
GUFICBIO · Healthcare · Pharmaceuticals & Biotechnology
Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra and currently employs 1,382 full-time employees. The company went IPO on 2004-10-19. The firm operates through the Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole and Everolimus. Its Gufic Stridden includes Irvical and Eve.
Equity review factors
Factor profile
Factor scores are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags and screen results for GUFIC BIO SC are part of the Wright portfolio review.
Run your free portfolio reviewFundamental snapshot
Fundamentals at a glance
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.